News Releases

News Releases

Jun 16, 2020
Generation Bio Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering
Jun 11, 2020
Generation Bio Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , June 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering
Mar 30, 2020
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
CAMBRIDGE, Mass. and SAN FRANCISCO, March 30, 2020 –  Generation Bio  and  Vir Biotechnology   (Nasdaq: VIR)  today announced a collaborative research agreement to explore the potential for Generation Bio’s non-viral gene therapy platform to extend the impact and reach of Vir’s current or future
Jan 10, 2020
Generation Bio to Present at 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 10, 2020 –  Generation Bio , a company leading a new generation of gene therapy, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020. President and Chief Executive Officer Geoff McDonough,